English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Serum prostate-specific antigen (PSA) has been recognized as a sensitive indicator of recurrent prostate cancer after radical prostatectomy (1)(2)(3)(4)(5). In the past 5 years, numerous PSA assays with improved limits of detection (6)(7)(8)(9)(10)(11)(12)(13)(14)(15) have been developed by both clinical researchers and diagnostic assay manufacturers. The rationale behind the development of more sensitive PSA assays (e.g., lower limits of detection) is that the relapse of prostate cancer or the tumor-doubling time after radical prostatectomy can be detected much earlier if patients are monitored with more sensitive assays (16)(17).Here we report a rapid enzyme immunoassay (EIA) for serum PSA at low concentrations by flow-injection electrochemical detection, which is based on the modification of the Tandem®-E PSA assay (Hybritech, San Diego, CA). EIA coupled with electrochemical detection offers low limits of detection with high specificity (18)(19)(20)(21). Electrochemical EIA is usually based on the conversion of an electroinactive substrate to an electroactive product by …

Electrochemical Enzyme Immunoassay for Serum Prostate-Specific Antigen at Low Concentrations